Australia: Power and purpose: Protecting a competitive position after ACCC v Pfizer

SUMMARY

On 25 May 2018, in ACCC v Pfizer,1 the Full Court confirmed that a patent owner with substantial market power may not necessarily be acting with an anti-competitive purpose if it seeks to protect its market position when faced with significant competitive threats in the lead up to patent expiry. On 25 June 2018, the ACCC announced that it had sought special leave to the High Court.

Australia's competition law has changed since the matter was brought and decided by two Courts, and the case may yet be heard by the High Court. However, the judgment provides some clarity on the issue of anti-competitive purpose. This is a central issue in pharmaceutical markets, where originator pharmaceutical companies continue to search for new ways to protect assets in which they have made substantial investments as patent expiry approaches.

When will an originator with a product approaching a 'patent cliff' retain sufficient market power to contravene Australia's competition law, and how should its actions to protect its competitive advantage be assessed?

BACKGROUND TO COURT ACTION

For over a decade, Pfizer's cholesterol lowering drug, Lipitor (molecule: atorvastatin), was the biggest-selling drug in the world. By the end of 2011, Lipitor was the highest selling drug in Australia in terms of both volume and value under the Pharmaceutical Benefits Scheme (PBS). Pfizer's patent over Lipitor gave it the exclusive right to supply atorvastatin in Australia until 18 May 2012. The patent expiry date was well known to, and a major event for, Pfizer and generic pharmaceutical suppliers.

The matter concerns Pfizer's attempts between 2011 and 2012 to combat the likely "erosion" of Lipitor's market share after patent expiry. In late 2010, Pfizer recognised that from early 2012 its marketing strategies would have to accommodate the inevitable switching of patients from Lipitor to generic atorvastatin.

To avoid being "slaughtered" in the market, Pfizer took a number of steps including:

  • the establishment in January 2011 of a supply model which involved Pfizer supplying pharmacies directly (rather than through wholesalers);
  • the establishment in January 2011 of an accrual funds scheme whereby Pfizer set aside a percentage of the price of purchases of Pfizer products (including Lipitor) to be rebated to pharmacies on terms to be announced at a later date (and not known by the pharmacies at the date of accrual);
  • in January 2012, making a bundled offer to pharmacies of Lipitor and generic atorvastatin, which Pfizer called atorvastatin Pfizer. This bundled offer tied the accrual funds scheme rebates to the quantity of Lipitor and atorvastatin Pfizer purchased by pharmacies. The more atorvastatin Pfizer purchased, the greater the proportion of the release of the pharmacy's accrual funds. Discounts on the price of atorvastatin Pfizer and Lipitor were also offered, dependent on the conversion rate from Lipitor to atorvastatin Pfizer.

CONTRAVENTIONS

The ACCC pleaded broadly the same case before the Full Court as it did before the primary judge.

The ACCC claimed that the above conduct contravened s 46(1)(c) of the Competition and Consumer Act 2010 (Cth) (CCA) by taking advantage of the substantial degree of market power which the ACCC alleged that Pfizer held in the market for the supply of atorvastatin to pharmacies (atorvastatin market) for an anti-competitive purpose, namely deterring or preventing generic manufacturers from engaging in competitive conduct.

In addition, the ACCC claimed that Pfizer had engaged in the practice of exclusive dealing within the meaning of section 47 CCA by requiring pharmacies who wished to acquire atorvastatin Pfizer also to purchase specified quantities of Lipitor, contravening a number of sub-sections of section 47 CCA. Section 47 CCA provides that exclusive dealing of this type is prohibited only if it is has the purpose or likely effect of substantially lessening competition. The ACCC ran its section 47 case as a "purpose" case and not as a "likely effect" case.

FULL COURT'S JUDGMENT

The Full Court accepted the ACCC's arguments in part. Foster, Greenwood and Middleton JJ concluded that:

  • unlike the primary judge, who found that by January 2012 Pfizer no longer had a substantial degree of market power, in both January and February 2012, when the bundled offers were made, Pfizer did retain a substantial degree of market power;
  • the primary judge was correct when he found that in 2010 and 2011, when Pfizer had market power, it took advantage of that market power by implementing the direct supply model and establishing the accrual funds scheme. However, the primary judge erred in concluding that in making the bundled offers in January and February 2012, Pfizer would not have taken advantage of its market power had any survived at that stage; and
  • importantly, the primary judge was correct that, at no time, did Pfizer act with an anti-competitive purpose.

MARKET POWER ON THE EDGE OF A 'PATENT CLIFF'

In finding that Pfizer continued to maintain substantial market power in January and February 2012, the Full Court clarified that even the prospect of "significant potential competition" from generic manufacturers, ahead of the expiry of the patent over the biggest drug on the market, was not enough to diminish the originator's substantial market power at that stage.

Pfizer's ability to introduce its own generic, as part of a bundled offer in January 2012, without seriously affecting the price of its Lipitor branded product, was critical to the Court's finding. The Full Court considered that Pfizer's behaviour demonstrated that it was not yet constrained by the future "inevitable" generic competition.

The finding that Pfizer, despite being faced with one of the most anticipated generic launches, possessed substantial market power until at least around three months before patent expiry suggests that originators' market power is likely to subsist until very close to patent expiry.

However, as the Court did not expressly state that Pfizer retained market power up to the date of patent expiry, it remains unclear exactly when Pfizer's market power diminished and what level of competitive conduct pre-patent expiry would have been enough to tip the balance of power away from Pfizer.

Several questions therefore remain.

  • Is it possible that there are other pharmaceutical markets (for other products) in which market power would subsist up until the date of patent expiry? These might include products which are not likely to be subject to such intense launches, products from which it is medically difficult to switch, very low-value products, or very high-value products. This finding highlights that originators will need to pay attention to the "effect" of sharp commercial practices in the months leading up to patent expiry.
  • On one view, as competitive generic entry could not occur until June 2012 (the PBS listing date for generic atorvastatin), it may be arguable that Pfizer did not lose substantial market power until this point in time, shortly after it lost exclusivity in the market.
  • As to what type of launch would count as a competitive threat, the decision suggests that only PBS launches would suffice. Alternatively, it is arguable that such an approach ignores the commercial realities of the pharmaceutical market and the bargaining that occurs between pharmaceutical companies and pharmacies in the months ahead of PBS listing. In this context, it is possible that market power does not continue to exist immediately prior to and at the date of patent expiry. However, such a view is at odds with the monopoly and exclusivity provided by a patent and a decision of the Full Court handed down last year, which held that an offer to supply post-patent expiry can amount to patent infringement where the offer is made during the term of the patent.2

PURPOSE, "TAKING ADVANTAGE" AND A NEW EFFECTS TEST

The Full Court confirmed that by their nature direct-to-pharmacy models, the accrual fund schemes, and the bundled offers could expose no anti-competitive purpose. Most importantly in this regard, the bundling of Lipitor with atorvastatin Pfizer in January and February 2012 was not evidence (of itself) of Pfizer having a proscribed purpose when it did so.

The Full Court judgment also confirms that protecting a market position in the face of competition does not expose an anti-competitive purpose. Even where internal documents used "offensive" language, such as "blocking" competition, in the circumstances, the Full Court considered that Pfizer's actions were "defensive" and it entered into the conduct to prevent inevitable share "erosion".

However, "colourful' language used in internal documents was persuasive for the ACCC in this regard. Those "blocking" documents were the focus of the ACCC's case and helped to create the controversy. While that characterisation found no favour with the primary judge or Full Court, this does not mean that language is any less important in internal documents after this case – and hyperbolic language of this type remains risky.

As well as determining the purpose of a corporation's actions, there is now an "effects test" to contend with. Australian competition law changed substantially in late 2017. The biggest change was to the unilateral conduct prohibitions. The old market power prohibition stopped corporations with market power from taking advantage of that power for a prohibited purpose (deterring entry or competitive conduct, or harming competitors). Now, the law prohibits corporations with market power from engaging in conduct with the purpose or effect of substantially lessening competition.

The Full Court considered only the purpose case(s) put before it. However, there are important takeouts for the new effects test universe. Atorvastatin was a major event for generic pharmaceutical suppliers. By June 2012, 77% of the atorvastatin market was being supplied by suppliers of generics.

The Full Court considered that, in context, the strategies Pfizer had developed and put in place were not expected to have effect in the market for very long and were not expected to achieve much more than gaining a "first-mover advantage" for Pfizer. Nothing Pfizer did changed those circumstances. Nor did it (realistically) expect any change. Similarly to the assessment of market power above, we question whether there are a range of pharmaceutical products where generics would not be likely to launch so effectively and intensely. In those circumstances, a Court could easily apply different reasoning to that which the Full Court employed. If "erosion" is expected to be substantially slower, or a position is more easily able to be defended – would the Full Court's conclusions have been the same under an effects test?

In the same way, an important element under an effects test could be that even though generics are able to engage in some competitive conduct pre-patent expiry, they cannot engage in the same conduct, in the same way, as the originator, or launch offers or products at the same time as the originator. This was a key point for the primary judge and Full Court with regard to the "taking advantage" test under the old law. In effect, the Courts asked whether a firm without market power in a workably competitive market could have taken the same action as Pfizer. For the Full Court, the answer was "no".

In these circumstances, could activity directed to obtain a "first mover advantage" (i.e. to get stock on the shelves of a chemist before other generic manufacturers) have the effect of substantially lessening competition? Even though the "taking advantage" limb has now been removed from the law, this context could be important in assessing the effects of similar conduct.

WHERE TO NEXT?

The ACCC has sought special leave from the High Court to appeal the Full Court's judgment. "The ACCC is seeking clarity ... on how to assess anti-competitive purpose", said an ACCC Commissioner.3 The ACCC is also seeking special leave on the issue of when a "requirements contract" will amount to exclusive dealing. The assessment of purpose is complex but well-trodden ground in Australian competition law and four seasoned competition law judges appear to be in violent agreement as to the nature and application of the purpose test in this matter. In those circumstances, it will be interesting to see the points of law on which the ACCC seeks to persuade the High Court to grant special leave.

Footnotes

1 Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd [2018] FCAFC 78. (ACCC v Pfizer)

2 Warner-Lambert Company LLC v Apotex Pty Limited [2017] FCAFC 58 at [6]-[7].

3 See https://www.accc.gov.au/media-release/accc-seeks-special-leave-to-appeal-full-federal-court%e2%80%99s-pfizer-judgment .

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Chambers Asia Pacific Awards 2016 Winner – Australia
Client Service Award
Employer of Choice for Gender Equality (WGEA)

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions